Matt Herper's model omits any discount for the risk of the FDA failing to approve Qnexa
That just makes it diverge further from reality...
There are certainly still skeptical analysts out there - Jefferies' Wei just raised his price target from $3 (!) to $10. He still believes that the FDA will likely require a pre-approval cardiac study.
Market Data 
Markets 
AI
